Publications
Export 79 results:
Filters: Author is M-A Roy [Clear All Filters]
, “A Chart Audit Study of Clozapine Utilization in Early Psychosis.”, J Clin Psychopharmacol, vol. 41, no. 3, pp. 275-280, 2021.
, “Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.”, J Psychopharmacol, vol. 35, no. 9, pp. 1152-1157, 2021.
, “Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program.”, CNS Drugs, vol. 35, no. 4, pp. 461-468, 2021.
, “Urbanicity, Schizophrenia and Equitable Specialist Services Allocation.”, Can J Psychiatry, p. 7067437211040606, 2021.
, “Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics.”, World J Biol Psychiatry, pp. 1-8, 2020.
, “The Evolution of Long-Acting Antipsychotics Use in Québec between 2003 and 2017.”, Can J Psychiatry, vol. 65, no. 7, pp. 510-511, 2020.
, “From QAAPAPLE 1 to QAAPAPLE 2: How do we move from one algorithm to another one with Long acting antipsychotics (LAIs).”, Expert Rev Neurother, 2020.
, “A multimodal attempt to follow-up linkage regions using RNA expression, SNPs and CpG methylation in schizophrenia and bipolar disorder kindreds.”, Eur J Hum Genet, vol. 28, no. 4, pp. 499-507, 2020.
, “Personalized cognitive remediation therapy to facilitate return to work or to school in recent-onset psychosis.”, Neurocase, vol. 26, no. 6, pp. 340-352, 2020.
, “Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports.”, J Clin Psychopharmacol, vol. 40, no. 2, pp. 191-194, 2020.
, “"Real world" clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients.”, Psychopharmacology (Berl), 2020.
, “Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence.”, J Clin Psychopharmacol, vol. 39, no. 4, pp. 393-397, 2019.
, “Determinants of occupational outcome in recent-onset psychosis: The role of cognition.”, Schizophr Res Cogn, vol. 18, p. 100158, 2019.
, “[Long-acting antipsychotics: The QAAPAPLE algorithm review].”, Can J Psychiatry, p. 706743719847193, 2019.
, “Continuing clozapine despite recurrent neutropenia: A 8 year follow-up case report with granulocyte-colony stimulating factor as-required use.”, Asian J Psychiatr, 2018.
, “Effects of Antiparkinson Medication on Cognition in Parkinson's Disease: A Systematic Review.”, Can J Neurol Sci, vol. 45, no. 4, pp. 375-404, 2018.
, “More intensive probing increases the detection of social anxiety disorders in schizophrenia.”, Psychiatry Res, vol. 268, pp. 358-360, 2018.
, “Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity.”, J Psychiatry Neurosci, vol. 43, no. 4, pp. 287-288, 2018.
, “Global Mapping of the Macrophage-HIV-1 Transcriptome Reveals that Productive Infection Induces Remodeling of Host Cell DNA and Chromatin.”, Sci Rep, vol. 7, no. 1, p. 5238, 2017.
, “[Initiating an antipsychotic drug treatment for schizophrenia: the situation in Quebec, Canada, from 1998 to 2006].”, Sante Ment Que, vol. 42, no. 1, pp. 85-103, 2017.
, “What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada?”, Can J Psychiatry, vol. 62, no. 2, pp. 109-114, 2017.
, “Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study.”, Acta Psychiatr Scand, vol. 134, no. 5, pp. 374-384, 2016.
, “An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.”, Clin Schizophr Relat Psychoses, vol. 9, no. 4, pp. 198-208, 2016.
, “A feasibility study of a new computerised cognitive remediation for young adults with schizophrenia.”, Neuropsychol Rehabil, vol. 26, no. 3, pp. 321-44, 2016.
